Phase III study

Novo Nordisk’s CagriSema outperformed the company’s flagship type 2 diabetes drug Ozempic (semaglutide) in both HbA1c levels and weight loss in a phase III trial. In the REIMAGINE 2 study (NCT06065540), CagriSema achieved a superior reduction in HbA1c of 1.91% points compared to 1.76% points with Ozempic after 68 weeks. CagriSema also led to a … Read more